Alex G. Howarth has been the CEO of Madrigal Pharmaceuticals, Inc. since July 2016. During his time, the company has focused heavily on research and development in the fast-paced biopharmaceutical industry. Under Alex's leadership, Madrigal has achieved significant milestones, including...
Alex G. Howarth has been the CEO of Madrigal Pharmaceuticals, Inc. since July 2016. During his time, the company has focused heavily on research and development in the fast-paced biopharmaceutical industry. Under Alex's leadership, Madrigal has achieved significant milestones, including navigating complex clinical trials and securing a strong market position. In 2023, Alex received a total compensation of $1,668,000, with a significant portion of this coming from performance bonuses, reflecting his ability to drive success and reach company goals. Interestingly, Alex has been quite active in insider trading, with notable fluctuations in his company stock holdings throughout 2023. For example, at the beginning of January 2023, the value of his holdings was around $4.47 million, dropping to $2.55 million by September, before spiking again to approximately $6.35 million by January 2024. This shows a dynamic approach to stock management and reflects both confidence in his leadership and awareness of market trends.